Celcuity’s Revtorpyk Gets FDA Nod, Delivering Strong Results in PIK3CA Wild-Type Breast Cancer
The new treatment, given with fulvestrant with or without palbociclib, nearly quadrupled progression-free survival versus standard therapy.
/ 7 items
#CELC↓
Celcuity’s Breast Cancer Drug Outperforms Rivals at ASCO, Yet Wall Street Still Reacts Negatively
Celcuity’s gedatolisib doubled progression-free survival (11.1 vs 5.6 months) compared with Novartis’ Piqray in a Phase 3 breast cancer trial presented at ASCO 2026, but fell short of high market expectations.
Sensei Biotherapeutics Gets Wall Street Backing as PIKTOR Advances in Breast & Endometrial Cancer
Cantor is bullish on Sensei Biotherapeutics for its cancer drug PIKTOR, with Phase 2 data soon as a key stock catalyst.
“Game-Changer” Breast Cancer Drug News Triggers H.C. Wainwright Upgrade for Celcuity
Celcuity’s drug showed strong results in breast cancer, boosting survival and raising hopes it could become a new standard treatment.
Celcuity Shares Surge After Gedatolisib Shows 76% Reduction in Disease Progression
Celcuity shares jump 45% after Phase 3 trial shows gedatolisib significantly improves survival in HR+/HER2- breast cancer patients. Analysts raise price target to $95.
Guggenheim's Buy Rating for Celcuity and Gedatolisib Potential
Financial firm Guggenheim gave Celcuity a Buy rating, predicting massive sales for its breast cancer drug, Gedatolisib.